Related references
Note: Only part of the references are listed.Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv192, 2018)
D. Planchard et al.
ANNALS OF ONCOLOGY (2019)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Sebastian Michels et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
Caicun Zhou et al.
LANCET RESPIRATORY MEDICINE (2019)
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
S. Novello et al.
ANNALS OF ONCOLOGY (2018)
Background and rationale of the eXalt3 tria investigating X-396 in the treatment of ALK plus non-small-cell lung cancer
Eric K. Singhi et al.
FUTURE ONCOLOGY (2018)
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer
Benjamin J. Solomon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
Makoto Nishio et al.
LUNG CANCER (2018)
The efficacy and safety of alectinib in the treatment of ALK plus NSCLC: a systematic review and meta-analysis
Junsheng Fan et al.
ONCOTARGETS AND THERAPY (2018)
Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
Zachary Schrank et al.
CANCERS (2018)
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK plus ) non-small-cell lung cancer: CNS efficacy results from the ALEX study
S. Gadgeel et al.
ANNALS OF ONCOLOGY (2018)
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D. R. Camidge et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset
Katsuyuki Kiura et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib
Trish Thorne-Nuzzo et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)
Byoung Chul Cho et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors
Stefan Michiels et al.
DRUGS (2017)
Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK plus non-small-cell lung cancer with or without prior crizotinib therapy
Toyoaki Hida et al.
CANCER SCIENCE (2016)
PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement
Jessie McGowan et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2016)
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014
Benjamin J. Solomon et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials
Haili Qian et al.
BMC CANCER (2014)
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer
Fiona Blackhall et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews
Rebecca M. Turner et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2012)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Bayesian measures of model complexity and fit
DJ Spiegelhalter et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2002)
Share Paper
